Valsts: Lielbritānija
Valoda: angļu
Klimata pārmaiņas: MHRA (Medicines & Healthcare Products Regulatory Agency)
Methyldopa (anhydrous)
Mawdsley-Brooks & Company Ltd
C02AB01
Methyldopa (anhydrous)
250mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02050200
PACKAGE LEAFLET: INFORMATION FOR THE USER MEDOMET 250 MG & 500 MG TABLETS METHYLDOPA 1. WHAT MEDOMET IS AND WHAT IT IS USED FOR 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE MEDOMET 3. HOW TO TAKE MEDOMET 4. POSSIBLE SIDE EFFECTS 5. HOW TO STORE MEDOMET 6. CONTENTS OF THE PACK AND OTHER INFORMATION The name of your medicine is Medomet. It contains the active ingredient Methyldopa, which belongs to a group of medicines called anti-hypertensives. Methyldopa is changed inside your body to a natural substance that lowers blood pressure. It is used to treat high blood pressure (hypertension). DO NOT TAKE MEDOMET IF YOU: have ever had a bad reaction, such as allergic (hypersensitive) to Methyldopa or to any of the other ingredients in this tablet (listed in section 6 of this leaflet) The signs of an allergic reaction include a rash, itching or difficulty breathing have active liver disease (such as hepatitis or cirrhosis) are suffering from depression have high blood pressure due to a tumour on the adrenal gland, near the kidney (phaeochromocytoma or paraganglioma) have an inherited blood disorder of the red blood pigment haemoglobin known as acute porphyria are taking MAOIs (monoamine oxidase inhibitors) for depression. Do not take this medicine if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Medomet. WARNINGS AND PRECAUTIONS Tell your doctor BEFORE you take this medicine if you: have kidney disease have jaundice (yellowing of the skin and eyes) have fever have any abnormal movements (involuntary) have liver problems suffer from an abnormal breakdown of red blood cells which can make the skin pale or yellow and cause weakness or breathlessness (haemolytic anaemia). OPERATIONS AND TESTS If you are going to have an operation, dialysis, a blood transfusion or an anaesthetic, tell your doctor, dentist or nurse that you are taking Medomet. Tell your doctor you are taking Medomet if you have a laboratory test where urine or blo Izlasiet visu dokumentu
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Methyldopa 250mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 283.00mg of methyldopa equivalent to 250mg anhydrous methyldopa Excipient with known effect: Each tablet contains sunset yellow (E110) For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet Yellow biconvex film coated tablets with an approximate diameter of 10.5mm either plain or coded MYD 250 on one side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Clinical indications: Methyldopa is indicated for hypertension. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY General considerations _Patients with renal impairment _ Methyldopa is largely excreted by the kidney, and the patients with impaired renal function may respond to smaller doses. Withdrawal of methyldopa is followed by return of hypertension, usually within 48 hours. This is not complicated generally by an overshoot of blood pressure. _Patients on treatment with other hypertensive agents _ Therapy with methyldopa may be initiated in most patients already on treatment with other antihypertensive agents by terminating these antihypertensive medications gradually, as required. Following such previous antihypertensive therapy, methyldopa should be limited to an initial dose of not more than 500 mg daily and increased as required at intervals of not less than two days. When methyldopa is given to patients on other antihypertensive the dose of these agents may need to be adjusted to effect a smooth transition. _Addition of a thiazide _ When 500 mg of methyldopa is added to 50 mg of hydrochlorothiazide, the two agents may be given together once daily. Many patients experience sedation for two or three days when therapy with methyldopa is started or when the dose is increased. When increasing the dosage, therefore, it may be desirable to increase the evening dose first. _Adults_ _ _ _Initial dosage:_ Usually 250mg two or three times a day, for two days, increased at i Izlasiet visu dokumentu